全球滑膜肉瘤治疗市场 – 行业趋势及 2030 年预测

 滑膜肉瘤治疗市场分析和规模

滑膜肉瘤是一种相对少见的癌症，被归类为分化不明的软组织肉瘤 (STS)。它占所有 STS 的 5-10%。年龄调整后的儿童发病率为 0.81/1,000,000，成人发病率为 1.42/1,000,000，美国每年约有 1000 名患者被诊断出患有滑膜肉瘤。滑膜肉瘤与其他 STS 不同，它的平均发病年龄较低，在青少年和年轻人中更为常见（诊断时的平均年龄为 39 岁），并且男女发病率相同。滑膜肉瘤是儿童中最常见的非横纹肌肉瘤 STS，占所有 STS 诊断的 30%。

Data Bridge Market Research 分析，滑膜肉瘤治疗市场在 2022 年的规模为 385 亿美元，预计到 2030 年将达到 568.8 亿美元，在 2023 年至 2030 年的预测期内的复合年增长率为 5%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

滑膜肉瘤治疗市场范围和细分  

Market Definition

Synovial Sarcoma is a rare type of cancer that develops near large joints, particularly the knee. This disease is most likely to affect people between the ages of 15 and 40. Synovial sarcoma is a type of cancer that grows slowly and is more common in men. It is also known as malignant myeloma. The most common symptoms of synovial sarcoma are swelling near the affected areas, which is often painless, and problems using both legs and hands. Synovial sarcoma is characterised by abnormal soft-tissue growth. Synovial sarcoma is highly metastatic and spreads to other locations in nearly 50% of cases, with the lungs being the most common site of metastasis. The cause of synovial sarcoma has not yet been determined, however, it has been linked to chromosome X and chromosome 18 abnormalities in tumour cells.

Global Synovial Sarcoma Treatment Market Dynamics

Drivers

• Rising incidence of synovial sarcoma

According to the American Cancer Society, the incidence of synovial sarcoma in the United States for 2018 is expected to be 13,040 patients, with 7,370 males and 5,670 females. Extensive research and development in this field for the development of novel therapies for the treatment of synovial sarcoma is expected to drive the growth of the global synovial sarcoma treatment market during the forecast period. For instance, Accuronix Therapeutics, Advenchen Laboratories, LLC, Immune Design, Cue Biopharma, and others, are conducting research and development of novel immunotherapy candidates for the treatment of synovial sarcoma.

• Technological advancements

The US Food and Drug Administration (FDA) designated Adaptimmune Therapeutics' NY-ESO-1 T-cell therapy as a T-Cell therapy breakthrough. Immunocore, a biotechnology company based in the United Kingdom, is developing ImmTAC (Immune mobilising monoclonal TCRs), which has potential applications in a variety of cancers, including synovial sarcoma. Furthermore, research on novel vaccines for the treatment of synovial sarcoma is underway, which could expand treatment options for the disease. During the forecast period, these factors are drive the growth of synovial sarcoma treatment market.

Opportunities

• Rising clinical trials

A robust and promising clinical pipeline is expected to fuel the synovial sarcoma treatment market in the near future. There are 83 pipeline therapeutics for synovial sarcoma treatment, with 8 drugs in clinical phase III. In addition, novel technologies such as ZVex and GLAAS technology, RESOLYSIN technology, and tumor-specific cytotoxic T-cell treatment are yielding promising results. Thus, a significant pipeline of drugs, growing public awareness, and increased funding for research are major factors driving market growth.

Restraints/Challenges

• High costs

The side effects associated with cancer treatment, high costs and uncertainty of the results of clinical trials are expected to affect the market's growth during the forecast period.

This synovial sarcoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the synovial sarcoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In Dec 2019, Adaptimmune Therapeutics plc announced that it has received the FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ADP-A2M4 to treat synovial sarcoma.

Global Synovial Sarcoma Treatment Market Scope

The synovial sarcoma treatment market is segmented on the basis of diagnosis, type, treatment, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Imaging
• Biopsy
• Others

Type

• ACXT-3102
• AL-3818
• Axitinib
• CMB-305
• CUE-102
• Others

 Treatment

• Surgery
• Anti-Angiogenesis
• Drugs Radiation Therapy
• Chemotherapy

 End-Users

• Hospitals
• Specialty Clinics
• Oncology Centers
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Synovial Sarcoma Treatment Market Regional Analysis/Insights

The synovial sarcoma treatment market is analyzed and market size insights and trends are provided by country, diagnosis, type, treatment, end-users and distribution channel as referenced above.

滑膜肉瘤治疗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美在滑膜肉瘤治疗市场占据主导地位，因为该产品的主要制造商数量众多，而且医疗保健支出不断增长，研发活动不断增加，从而促进了市场的显著增长。

由于滑膜肉瘤治疗市场的新研究和发展不断进步，预计亚太地区在 2023 年至 2030 年的预测期内将以最高的增长率增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

滑膜肉瘤治疗市场还为您提供了每个国家/地区资本设备医疗保健支出增长、滑膜肉瘤治疗市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对滑膜肉瘤治疗市场的影响的详细市场分析。数据适用于 2011-2021 年的历史时期。

竞争格局和滑膜肉瘤治疗市场份额分析

滑膜肉瘤治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对滑膜肉瘤治疗市场的关注有关。

滑膜肉瘤治疗市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd（瑞士）
• 拜耳公司（德国）
• Epizyme (美国)
• Cue Biopharma（美国）
• 礼来公司 (美国)
• Adaptimmune Therapeutics Plc（英国）
• Advenchen Laboratories LLC（美国）
• EpiZyme Inc（美国）
• 默克公司（美国）
• Immunocore Ltd（英国）
• 强生私人有限公司（美国）
• Karyopharm Therapeutics Inc（美国）
• 诺华公司（瑞士）
• 辉瑞公司（美国）
• Takara Bio Inc（日本） 

SKU-56902